Advertisement

Cardiovascular Toxicology

, Volume 8, Issue 1, pp 41–44 | Cite as

QT Prolongation: A Case of Arsenical Pericardial and Pleural Effusion

  • Enrico Vizzardi
  • Gregoriana ZaniniEmail author
  • Elena Antonioli
  • Antonio D’Aloia
  • Riccardo Raddino
  • Livio Dei Cas
Article

Abstract

Arsenic trioxide is an effective treatment for patients with acute promyelocytic leukaemia (APL) who have relapsed from or are refractory to all trans-retinoic acid and anthracycline chemotherapy. Cardiac effects observed include electrocardiographic changes such as QTc prolongation, T-wave abnormalities, torsades de pointes and sudden death. We describe a case of a man, 76 years old, who was admitted to our department for dyspnoea in APL in treatment with arsenic trioxide. Chest radiograph illustrated an enlarged cardiac silhouette and bilateral pleuric effusion and the ECG evidenced QT prolongation. The patient was also submitted to transthoracic echocardiography that revealed moderate pericardial effusion without signs of cardiac tamponade and a normal biventricular function. This condition was considered to be associated with arsenic trioxide polyserosit and the drug therapy was immediately discontinued and steroid drugs started. After 2 weeks of arsenic trioxide therapy suspension there was evidence of complete resolution of pericardial and pleuric effusion and the ECG showed normal QT interval.

Keywords

Arsenic trioxide QT prolongation Cardiac tamponade 

References

  1. 1.
    Barbey, J. T., Pezzullo, J. C., & Soignet, S. L. (2003). Effect of arsenic trioxide on QT interval in patients with advanced malignancies. Journal of Clinical Oncology, 21, 3609–3615.PubMedCrossRefGoogle Scholar
  2. 2.
    Shen, Z., Chen, G., & Ni, J. (1997). Use of arsenic trioxide in the treatment of APL, clinical efficacy and pharmacokinetics in relapsed patients. Blood, 89, 3354–3360.PubMedGoogle Scholar
  3. 3.
    Niu, C., Yan, H., Yu, T., et al. (1999). Studies on treatment of acute promyelocytic leukaemia with arsenic trioxide: remission induction, follow-up, and molecular monitoring in 11 newly diagnosed and 47 relapsed acute promyelocytic leukemia patients. Blood, 94, 3315–3324.PubMedGoogle Scholar
  4. 4.
    Soignet, S. L., Frankel, S. R., Douer, D., et al. (2001). United States multicenter study of arsenic trioxide in relapsed acute promyelocytic leukemia. Journal of Clinical Oncology, 19, 3852–3860.PubMedGoogle Scholar
  5. 5.
    Westervelt, P., Brown, R. A., Adkins, D. R., Khoury, H., et al. (2001). Sudden death among patients with acute promyelocytic leukemia treated with arsenic trioxide. Blood, 98, 266–271.PubMedCrossRefGoogle Scholar
  6. 6.
    Tallman, M. S., Andersen, J. W., Schiffer, C. A., et al. (1997). All trans retinoid acid in acute promyelocytic leukemia. The New England Journal of Medicine, 337, 1021–1028.PubMedCrossRefGoogle Scholar
  7. 7.
    Chanan-Khan, A., Srinivasan, S., & Czuczman, M. S. (2004). Prevention and management of cardiotoxicity from antineoplastic therapy. Journal of Supportive Oncology, 2(3), 251–256.PubMedGoogle Scholar
  8. 8.
    Jones, R. L., & Ewer, M. S. (2006). Cardiac and cardiovascular toxicity of nonanthracycline anticancer drugs. Expert Review of Anticancer Therapy, 6(9), 1249–1269.PubMedCrossRefGoogle Scholar
  9. 9.
    Drolet, B., Simard, C., & Roden, D. M. (2004). Unusul effects of a QT-prolonging drug, arsenic trioxide, on cardiac potassium currents. Circulation, 109, 26–29.PubMedCrossRefGoogle Scholar
  10. 10.
    Ghavamzade, A., Alimoghaddam, K., Ghaffari, S. H., et al. (2006). Treatment of acute promyelocytic leukemia with arsenic trioxide without ATRA and/or chemotherapy. Annals of Oncology, 17, 131–134.CrossRefGoogle Scholar
  11. 11.
    Klaassen, C. D. (2001). Heavy metals and heavy-metal antagonists. In J. G. Hardman, L. E. Limbird, & G. A. Goodman (Eds.), Goodman & Gilman’s the pharmacological basis of therapeutics (pp. 1851–1875). New York: McGraw-Hill.Google Scholar

Copyright information

© Humana Press Inc. 2007

Authors and Affiliations

  • Enrico Vizzardi
    • 1
  • Gregoriana Zanini
    • 1
    Email author
  • Elena Antonioli
    • 1
  • Antonio D’Aloia
    • 1
  • Riccardo Raddino
    • 1
  • Livio Dei Cas
    • 1
  1. 1.Section of Cardiovascular Disease, Department of Applied Experimental MedicineBrescia Study UniversityBresciaItaly

Personalised recommendations